VAI TRÒ CỦA PI-RADS PHIÊN BẢN 2.1 TRÊN CỘNG HƯỞNG TỪ TRONG CHẨN ĐOÁN UNG THƯ TIỀN LIỆT TUYẾN

Abstract

Background: Prostate cancer is the second most commonly occurring cancer in men and the fifth most common cancer overall. The introduction of the Prostate Imaging Reporting And Data System version 2.1 (PI-RADS 2.1) in March 2019 has significantly improved the uniformity of interpreting imaging findings, leading to enhanced precision in diagnosis. Objective: To assess the effectiveness of magnetic resonance imaging based on the PI-RADSv2.1 guideline in identifying prostate cancer. Detection of clinically significant prostate cancer with PI-RADS v2.1 scores. Methods: A retrospective study included 84 patients who presented with clinical suspicion of prostate cancer (based on clinical presentation or elevated PSA levels). Prostate MRI evaluations were performed using the PI-RADS 2.1 criteria, followed by transrectal ultrasound-guided biopsy. The study period was conducted from January 2022 to December 2023. Results: A total of 84 patients with a mean age of 70 years and a median PSA level of 24,4 ng/ml were included in the study. The detection rates of prostate cancer for lesions classified as PI-RADS 2, 3, 4, and 5 were 12.9%, 27.2%, 77.3%, and 96.3%. Furthermore, the overall Gleason score is positively correlated with an elevated PI-RADS v2.1 score. Conclusions: The utilization of MRI prostate with the PI-RADS 2.1 demonstrates significance in accurately detecting prostate cancer.